# Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

> **NCT07174453** · PHASE3 · RECRUITING · sponsor: **University of Kansas Medical Center** · enrollment: 192 (estimated)

## Conditions studied

- Solid Tumor Malignancies

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Pembrolizumab

## Key facts

- **NCT ID:** NCT07174453
- **Lead sponsor:** University of Kansas Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-07
- **Primary completion:** 2027-10-01
- **Final completion:** 2029-10-01
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2025-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07174453

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07174453, "Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT07174453. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*